Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-cash Items (2023 - 2025)

Monte Rosa Therapeutics' Non-cash Items history spans 3 years, with the latest figure at $115.2 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 909.24% year-over-year to $115.2 million; the TTM value through Dec 2025 reached $115.2 million, up 909.24%, while the annual FY2025 figure was $115.2 million, 1717.08% up from the prior year.
  • Non-cash Items reached $115.2 million in Q4 2025 per GLUE's latest filing, up from $15.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $115.2 million in Q4 2025 to a low of $3.7 million in Q3 2023.
  • Average Non-cash Items over 3 years is $17.7 million, with a median of $8.7 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: crashed 42.36% in 2024, then skyrocketed 909.24% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $4.7 million in 2023, then skyrocketed by 140.86% to $11.4 million in 2024, then surged by 909.24% to $115.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Non-cash Items are $115.2 million (Q4 2025), $15.8 million (Q3 2025), and $8.1 million (Q2 2025).